Literature DB >> 25270687

Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.

Xingwang Zhang1, Huan Wang, Zhiguo Ma, Baojian Wu.   

Abstract

INTRODUCTION: PEGylation refers to covalent conjugation of one or more polyethylene glycol chains to a drug molecule. It also refers to formulation of a drug into PEGylated drug-delivery vehicles in pharmacy. It is well-known that PEGylation can greatly influence the pharmacokinetics and pharmacodynamics of drugs. AREAS COVERED: This article describes the importance of PEGylation in drug development and research. The impact of PEGylation on drug metabolism and the clinical safety of PEGylated drugs (or formulations) are also discussed. Information and data from the literature were collected, analyzed and summarized. EXPERT OPINION: PEGylation is an effective approach to potentiate drugs with undesirable properties. Currently, PEGylation has penetrated into every field of pharmaceutical practice, involving biomacromolecules, small drugs and drug delivery systems. Efficacy enhancement is attained through modification of the pharmacokinetics and toxicity profiles of parent drugs. As a result of PEGylation, the drugs tend to display enhanced solubility, prolonged circulatory time and reduced immunogenicity/antigenicity. The bottleneck of PEGylation is how to break through the limitation of chemical conjugation and to properly preserve the pharmacological activity of the drug. PEGylated formulation is an area deserving more attention in terms of systemic delivery of insoluble small drugs.

Entities:  

Keywords:  PEGylation; clinical concerns; metabolism; proteins and peptides; small-molecule drugs

Mesh:

Substances:

Year:  2014        PMID: 25270687     DOI: 10.1517/17425255.2014.967679

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  19 in total

1.  Pre-Assembly of Near-Infrared Fluorescent Multivalent Molecular Probes for Biological Imaging.

Authors:  Evan M Peck; Paul M Battles; Douglas R Rice; Felicia M Roland; Kathryn A Norquest; Bradley D Smith
Journal:  Bioconjug Chem       Date:  2016-04-27       Impact factor: 4.774

Review 2.  An update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Pavan Bhargava; Scott D Newsome
Journal:  Ther Adv Neurol Disord       Date:  2016-08-08       Impact factor: 6.570

Review 3.  Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines.

Authors:  Esperanza Padín-González; Pearl Lancaster; Massimo Bottini; Paolo Gasco; Lang Tran; Bengt Fadeel; Terence Wilkins; Marco P Monopoli
Journal:  Front Bioeng Biotechnol       Date:  2022-06-07

Review 4.  New paradigms in GPCR drug discovery.

Authors:  Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2015-08-08       Impact factor: 5.858

5.  Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.

Authors:  Marisa Boff Costa; Paulo Dornelles Picon; Guilherme Becker Sander; Hugo Nodarse Cuni; Carmen Valenzuela Silva; Rolando Páez Meireles; Ana Carolina Magalhães Andrade Góes; Nadia Maria Batoreu; Maria de Lourdes de Sousa Maia; Elizabeth Maciel Albuquerque; Denise Cristina de Souza Matos; Pedro Lopez Saura
Journal:  BMC Pharmacol Toxicol       Date:  2018-01-04       Impact factor: 2.483

6.  In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library.

Authors:  Hanlu Wang; Yibang Zhang; Haiping Yang; Meng Qin; Xinxin Ding; Rihe Liu; Yongping Jiang
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-09       Impact factor: 8.886

7.  Nanoemulsions as novel oral carriers of stiripentol: insights into the protective effect and absorption enhancement.

Authors:  Rong Lu; Shan Liu; Qilin Wang; Xia Li
Journal:  Int J Nanomedicine       Date:  2015-07-31

8.  Micellar emulsions composed of mPEG-PCL/MCT as novel nanocarriers for systemic delivery of genistein: a comparative study with micelles.

Authors:  Tianpeng Zhang; Huan Wang; Yanghuan Ye; Xingwang Zhang; Baojian Wu
Journal:  Int J Nanomedicine       Date:  2015-10-01

Review 9.  Critical questions in development of targeted nanoparticle therapeutics.

Authors:  Richard Korsmeyer
Journal:  Regen Biomater       Date:  2016-03-21

10.  Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.

Authors:  R Stidl; S Fuchs; M Bossard; J Siekmann; P L Turecek; M Putz
Journal:  Haemophilia       Date:  2015-07-29       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.